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1. Introduction 
Perhaps among the central nervous system (CNS) conditions with muscle hyperactivity, 
dystonia and spasticity figure as those that are disabling and requiring therapeutic 
intervention. Dystonia is a neurological syndrome characterized by sustained muscle 
contractions usually producing twisting and repetitive movements or abnormal postures. 
The sustained movements of dystonia may have overlying spasms similar to tremor but 
have a directional preponderance. Three other important clinical features of dystonia are 
occurrences of pain, sensory trick phenomenon (i.e. touching “hot spots” in body surface 
that abolishes the dystonia), and changes in severity depending on activity and posture . 
Spasticity is typified by a velocity-dependent occurrence of a “catch” following passive limb 
movement. Recently, the scope of spasticity has been broadened in its definition as a 
disordered sensori-motor control resulting from an upper motor neuron (UMN) lesion 
presenting as intermittent or sustained involuntary activation of muscles(1-2) . Although 
their etiopathogenesis differ, both conditions overlap as regard the following: [a] occurrence 
of muscle co-contractions; [b] Overactivity involves not only extrafusal but also intrafusal 
muscles(3-4) [c] Intrinsic muscle changes in size and visceco-elastic properties (5-6); [d] 
contractures if left unattended (7);[e] muscular spread in synergy, “overflow” and 
compensatory muscles; [f ] loss of dexterity; [g] occurrence of pain to varying degrees; [h] 
secondary bone and joint abnormalities; [i] may lead to “compensatory circuitry changes” at 
segmental and suprasegmental levels (4) ; [j] May lead to posturing and cosmesis issues, and 
[k] hygiene, quality of life and social impact . Another common thread between dystonia 
and spasticity is the reduction in muscle tone following botulinum neurotoxin therapy 
(BoNT), and effectively addressing the disordered sensori-motor control in both conditions. 
Intuitively, BoNT will be most efficacious in cases with a combination of spasticity and 
dystonia (i.e. spastic dystonia), such as in childhood spasticity(8). This chapter summarizes 
the clinical efficacy of BoNT in both dystonia and spasticity.  
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2. BoNT: Peripheral blockade and beyond  
There are two kinds of BoNT (type A [BoNT-A: onabotulinumtoxinA or Botox®, 
abobotulinumtoxinA or Dysport ® and incobotulinumtoxinA or Xeomin®], and type B [BoNT-B: 
rimabotulinumtoxinB or Neurobloc®/Myobloc®]) that have been proven to be safe and 
effective in treating various hyperfunctional cholinergic states. Their therapeutic 
applications range from various forms of muscle hyperactivity (e.g. dystonia, spasticity, 
spasms, tremors, and tics), autonomic hyperactivity (e.g. drooling, hyperhidrosis and 
bladder overactivity) and cosmesis (e.g. frown lines and “crow’s feet). BoNT is more 
effective in blocking active neuromuscular junctions(9), and this effect can be enhanced by 
electric stimulation of the peripheral nerve(10). This toxin disrupts neurotransmission by 
cleavage of pre-synaptic vesicle fusion proteins; SNAP-25 for BoNT-A and synaptobrevin 
for BoNT-B, effectively blocking release of acetylcholine to the neuromuscular junctions and 
induce chemodenervation. The BoNT-A initially binds presynaptically (via the heavy chain 
attachment domain) and enters neurons by binding to the synaptic vesicle protein SV2(11). 
The toxin then undergoes internalization by vesicle endocytosis and translocation into the 
cytosol, to eventually exert its light chain proteolytic activity(12). After injection, the BoNT 
complex dissociates and diffuses into the target tissues. Toxin spread is a fast and active 
phenomenon that is driven by BoNT dose, dilution, needle size, and injection technique 
among others(13) . Subclinical effects of BoNT on endplates far away from the injected sites 
can be demonstrated by increased jitter in single-fiber electromyography (SFEMG) in 
animals(3,14) and humans(15-16). Clinically not relevant for the moment and taken with a 
cautious stand because of the high animal doses applied, BoNT may undergo retrograde 
axonal transport, possibly transcytosed to afferent neurons, in which it cleaves its substrate 
SNAP-25. BoNT-truncated SNAP-25 appears not only at the injection site but also in distant 
regions that project to the infusion area. This retrograde spread was blocked by colchicine, 
pointing to a likely involvement of microtubule-dependent axonal transport(17). BoNTalso 
affects the cholinergically mediated intrafusal fibers of muscle spindles, parallel to that of 
extrafusal fibers , implying an important functional effect (see a review on the subject by 
Rosales and Dressler, 2010[4]). In healthy, dystonic or spastic adults, the effect on muscle 
spindles appear to be more prolonged than that in extrafusal fibers, and whether one applies 
studies using the tonic vibration reflex (TVR)(18-19); or the transcranial magnetic 
stimulation(20). Since the gamma-motor-neurons are unable to activate the intrafusal fibers 
with BoNT-A, the muscle spindle output via the afferent axons will be reduced, and because 
muscle activity is supported by afferent feedback, there may be reduced alpha-motor-
neuron drive(3). These events imply that there could be potential modulation of central 
motor programs following BoNT-A(21). In fact, recent BoNT-A studies in dystonia and 
spasticity have shown evidences of modifications in the cortical and subcortical levels(22-
24); including plasticity changes(25).  
3. BoNT for dystonia  
3.1 Rationale 
Dystonia is a multi-level system disorder where involvement spans from the peripheral 
(muscular) to the segmental and suprasegmental levels (brainstem, basal ganglia and 
cortex)(4,26). Muscle hypertonus/spasms in dystonia are relieved by chemodenervation 
procedures that include muscle-based injections (i.e. muscle afferent block [MAB] and 
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BoNT) and near nerve injections (i.e. phenol block). Although useful in near large nerve 
injections (e.g. obturator and femoral nerves), phenol has not been encouraging because of 
pain associated with the procedure and its unpredictable response (27) . Hinged on the 
abolition of abnormal muscle spasms with “sensory trick” and MAB in dystonia (i.e. 
applying TVR[28]), it is believed that the BoNT does have sensory modulatory effects, apart 
from pure muscle relaxation (see a recent review on the subject by Kanovsky and 
Rosales[26]). In addition, BoNT-A may reduce pain comorbidity that occur in dystonia (see a 
recent review by Rawicki and cohorts[29]). The fact that BoNT injections are able to improve 
an individual’s occupational function and quality of life elevates the rationale for its 
applications. The latter is best exemplified by occupational dystonias (A separate chapter is 
dedicated to this end). Figure-1 depicts cases of focal hand dystonias with task-specificity 
and those with complex regional pain syndrome, being prepared for BoNT-A injections. 
  
  
Fig. 1. Focal hand dystonias (upper panel: with task-specificity [Writer’s cramp and Barber’s 
cramp]); (lower panel: with complex regional pain syndrome) 
3.2 Evidence-based medicine 
Cochrane reviews summarized the evidences of BoNT superiority as a therapy for 
blepharospasm(30) and cervical dystonia(31). The American Academy of Neurology 
(AAN)(32) recommended that BoNT injections should be offered as a treatment option for 
cervical dystonia (established as effective) and may be offered for blepharospasm, focal 
upper extremity dystonia, adductor laryngeal dystonia (probably effective). A lower level of 
evidence was detected for focal lower limb dystonia (possibly effective). According to the 
European Federation of Neurological Societies [EFNS] version(33), BoNT-A is considered 
the first-line treatment for primary cranial (except oromandibular) or cervical dystonia; it is 
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also effective for writing dystonia; BoNT-B is not inferior to BNT-A in cervical dystonia. 
Despite the variety of trial formats, virtually all the trials individually, and each outcome 
measure (objective and subjective) separately, suggested that a single injection cycle of BoNT-
A is effective and safe for treating cervical dystonia. Enriched trials (using patients previously 
treated with BoNT-A), suggest that further injection cycles continue to work for most patients. 
Appropriate injections of BoNT-A into cervical muscles at therapeutic doses are well tolerated, 
and although adverse effects occur these are transient and rarely severe(31). Furthermore, the 
available evidence suggests that BoNT-A injections provide more objective and subjective 
benefits than an anticholinergic drug (i.e. trihexyphenidyl) to patients with cervical 
dystonia(34). 
An international consensus on the aftercare for cervical dystonia and other causes of 
hypertonia of the neck stated that the benefits following BoNT injection include increased 
range of movement at the neck for head turning, decreased pain, and increased functional 
capacity (Class I evidence, level A recommendation). The evidence for efficacy and safety in 
patients with secondary dystonia in the neck is unclear based on the lack of rigorous 
research conducted in this heterogeneous population (level U recommendation). 
Psychometrically sound assessments and outcome measures exist to guide decision-making 
(Class I evidence, level A recommendation). Much less is known about the effectiveness of 
therapy to augment the effects of the injection (Class IV, level U recommendation). More 
research is needed to answer questions about safety and efficacy in secondary neck 
dystonia, effective adjunctive therapy, dosing and favourable injection techniques(35).  
On the issues of BoNT-A application in secondary dystonia as well as for oromandibular 
dystonia, an applied example is the case of x-linked dystonia-partkinsonism (XDP), a type of 
heredo-degenerative disorder . In the large cohort of oromandibular and lingual dystonias 
found in XDP, BoNT-A was shown to be safe and effective as one carefully navigates 
through recommended technical considerations(36). In XDP as well, BoNT-A targeted in 
cervical and limb dystonias, indicated its superiority over MAB(37). Interestingly, BoNT-A 
may also be combined with pallidal deep brain stimulation (DBS) in XDP(38), when the 
former eventually fails as the only treatment, or when toxin doses increase due to body area 
spread of dystonia, or even in certain instances after DBS .  
3.3 Clinical context  
BoNT is a safe and targeted treatment approach suited for focal dystonia where certain 
muscles are clearly involved during co-contraction and in which injections can be modified 
for the changing dystonia patterns, including segmental and overflow muscles involved 
(4,13,26). Depending upon factors such as muscle bulk, severity of muscle spasm and 
whether one may want/avoid contiguous muscles in a clinical context, BoNT-A in dystonia 
may be tailored in certain instances. A “high potency, low dilution” of BoNT-A may best be 
applied in the cranio-cervical (i.e. injections in the peri-ocular, facial, oromandibular, 
lingual, laryngeal and neck muscles) and distal limb regions, where BoNT-A is expected to 
be maximized in a targeted (usually smaller) muscles through 1–2 injection sites, and where 
spread is best avoided. Whereas, in dystonias of the abdominal, paraspinal, and proximal 
limb muscles, a “low potency, high dilution” BoNT-A injection protocol could best be 
applied, since spread may be desirable for very large muscles, when multipoint muscle 
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injections is utilized (36). In view of its “dual effects” on the extrafusal and intrafusal 
muscles, the clinical benefit in practice may “outstrip” the weakness induced by the 
BoNT(4,39) . Interestingly in cervical dystonia, discrepant and time-related effects vary 
between relief of muscle hypertonus, associated pain and head posture(31) . These findings 
underscore the BoNT effects far beyond simply blocking muscle spasms in dystonia. For 
instance, the head posture may be related to muscle spindle changes among other factors(4) 
and the associated pain relief having perhaps an independent mechanism(29) . The role of 
BoNT-A in pain pathophysiology is beginning to be understood, however, larger studies in 
neuropathic pain, joint pain, and myofascial pain syndrome are needed to fully ascertain 
robustness of BoNT therapy in those areas(40-41). 
4. BNT for spasticity 
4.1 Rationale 
Arguably only one component of UMN, spasticity in both children (e.g. cerebral palsy, see 
Figure-2) and adults (e.g. post-stroke, traumatic brain/spinal injuries and multiple sclerosis; 
see Figure-3), may impair one’s motor control, quality of life and may eventually lead to 
economic and care-giver burden. More than one third of patients develop spasticity within 
  
Fig. 2. Childhood spasticity (thigh adductor spasms or “scissoring” and equinovarus foot 
deformity) 
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Fig. 3. Spasticity “plus”(Post-stroke with spastic dystonia-left panel; Multiple Sclerosis with 
spastic dystonia-middle panel; Traumatic brain injury with spasticity and dynamic 
contracture-right panel) 
12 months after stroke(42-43) and a proportion of these patients will develop disabling 
spasticity requiring intervention(44). Even in the early phases of stroke (“evolving 
spasticity”[45]) about 19% of patients(46) or possibly more(47), develop spasticity within 3 
months after the ictus. In fact, as many as 80% of patients without useful functional arm 
movement after the ictus, develop spasticity (measured by muscle activation recording) 
within 6 weeks of first stroke(48). 
Strokes in the middle cerebral artery region occur in three quarters of patients, hence, the 
upper limb is affected in a large number of them. In regard to therapeutic intervention, 
differences may arise between the hemiplegic upper and lower limbs, and these are(49): (a) 
functional recovery of an arm that enables grasping, holding, and manipulating objects, 
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requires the recruitment and complex integration of muscle activity from the shoulder to the 
fingers. In contrast, a minimal (or less complex) amount of recovery of a hemiplegic leg may 
be sufficient to obtain functional ambulation; (b) the ability to reach and grasp is a necessary 
component of many daily life functional tasks, hence reduced upper limb function is likely 
to reduce independence and increase burden of care. Moreover, muscles in the affected 
ankle cannot be efficiently recruited in a timely manner to overcome reaching task 
impairment in stroke patients (50); (c) left uncorrected, secondary complications such as 
inferior subluxation of the glenohumeral joint, shoulder-hand syndrome, soft tissue lesions, 
and painful shoulder further hinder rehabilitation of the hemiplegic arm; (d) there is a lack 
of spontaneous stimulation when performing upper limb functional activities that “assist” 
in recovery, compared to lower limb activities. Bilateral activity in the legs is often required 
whenever a patient attempts to transfer, stand or walk, whereas, in performing upper limb 
activities, the patient may opt to simply use the non-affected side exclusively(51); and, (e) 
the “protective effect” of spasticity applies more to the lower limbs, and not necessarily for 
the upper limbs. For example, lower limb spasticity may be beneficial by enabling patients 
to stand despite the co-occurrence of lower limb weakness. When it does cause harm, 
however, treatment is required(51-52). Spasticity in the upper limbs (ULS), with these 
inherent characteristics, may lead to compensatory central nervous system adaptations and 
changes after stroke such as the “learned non-use” of the affected upper limb. As a form of 
maladaptive plasticity, the frequent assistance of the non-affected limb may prove to be 
disadvantageous in the efforts to improve functional recovery(45). Not all patients with ULS 
will have spasticity-related symptoms (i.e. symptomatic spasticity), but those with functional 
impairment can be categorized into: (a) those relating to passive function, e.g. hand hygiene, 
wearing of upper garment, application of splints; (b) pain; (c) associated reaction, and (d) 
those relating to impaired active function(53). Therefore, it is not unusual that a large 
majority of BoNT randomized and systematic spasticity intervention studies have been 
performed on the upper limbs(54). Having its effect in the neural component of 
spasticity(2,55), the rationale for BoNT-A use is hinged on its reduction of muscle tone via 
chemodenervation of injected overactive muscles, and potentially prevent, through early 
injection protocols, eventual complications brought about by the non-neural components 
(e.g. contracture in spasticity, Fig-3)(45). In fact, BoNT-A is likewise able to address muscle 
overactivity in spasticity with associated reactions and dystonia (spastic dystonia; Fig-3) 
(45). The current state of knowledge on the application of BoNT-A in the management of 
spasticity is depicted in Figure-4.  
4.2 Evidence-based medicine 
Based on meta-analysis derived from well-conducted, randomized controlled clinical 
trials(54) BoNT-A proved to be safe and efficacious in treating upper and lower limb 
spasticity, as measured by lowering the Modified Ashworth Score (MAS) that clinically 
assesses hypertonicity during passive range of motion across a joint(56). A contemporary 
review on ULS also indicated robust efficacy of BoNT-A, over other pharmacologic 
therapies(57). Systematic reviews from the AAN (58), Royal College of Physicians (UK-
RCP)(59), European Consensus (60) and Movement Disorders Society (MDS)(61) lead to 
formulation of therapeutic guidelines for the application of BoNT-A in the over-all 
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Fig. 4. A schematic diagram on the current state of knowledge on the roles of  botulinum 
neurotoxin injections type A (BoNT-A) in spasticity management;  MAS-Modified Ashworth 
Scale; EMG-Electromyography; GIC-Global impression of change; DAS-Disability 
Assessment Scale; GAS-Goal Attainment Scaling 
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management of spasticity. In parallel, international consensus statements were made on the 
use of BoNT-A over a wide range of indications for adult and childhood spasticity(62-65). 
The benefit from BoNT-A is maintained after repeated treatment cycles(66-67) and thus, 
BoNT-A has been thought to be a first line treatment in focal/multifocal spasticity(68). In 
addition, BoNT treatment has been shown to improve associated reactions in ULS(69) 
reduce predetermined disability parameters (including pain) (70-73), reduce carer 
burden(70,73-74), improve person-centered goals(75) and self-reported efficacy with 
safety(76). However, efficacy of BoNT-A for improvement of motor control and active 
functions have not been attained(77). While spasticity is an important component of 
reduced upper limb function, Shaw and colleagues(71) argue that motor weakness is the 
most important factor. Likewise, their study did not demonstrate improved active function 
(despite an improvement in muscle tone in favor of intervention), arguably suggesting that 
spasticity is of less importance . To date, most of the studies show that BoNT-A injection has 
been applied in the chronic stage(78-80) (i.e.more than 6 months after stroke; average of 2.5 
years) wherein spasticity has been established(45) and wherein non-neural, rheologic 
changes have set-in. Early intervention with BoNT-A (i.e. less than 3 months post-stroke) 
has been performed in two Phase II trials (designed to estimate sample sizes)(81-82) and in a 
Phase III trial(83). The first Phase II study by Cousins and associates(81) indicated some 
functional recovery at 20 weeks in the groups that received onabotulinumtoxinA, following a 
subanalysis of patients with no arm function (employing Action Research Arm Test) in the 
baseline assessment (i.e. 3 weeks post-stroke). Interestingly, the second Phase II study by the 
German group(82) failed to demonstrate improvement in motor control with the Fugl-
Meyer arm score, despite a reduction in finger flexor stiffness, 6 months after injecting 
incobotulinumtoxinA. The Asian Botulinum Toxin Clinical Trial Designed for Early Post-
Stroke Spasticity (ABCDE-S) was a Phase III study (83) that demonstrated reduction in 
muscle tone (MAS) at week 4, and which was sustained to 24 weeks, despite a single cycle, 
uniform injection of 500units abobotulinumtoxinA. In the latter cohort of patients that 
enrolled patients 2 -12 weeks post- stroke, significant pain reduction (i.e. weeks 4 and 24) 
was demonstrated among those that had initial spasticity-related pain, but showed no motor 
control improvement (using the Motor Assessment Scale).  
4.3 Clinical context 
Spasticity has been shown to inhibit active upper limb function(84) mainly because the 
prime mover is not fully able to overcome the resistance of the spastic (antagonist) muscle. 
BoNT-A should be used to address specific functional limitations resulting from focal 
spasticity (i.e . muscle over-activity confined to one or a group of muscles that contribute to 
a specific functional problem). However, BoNT-A is not always expected to fully or partially 
recover lost function, except perhaps when that function has been lost primarily due to 
antagonist muscle over-activity(59) The effect of BoNT-A on muscle tone and muscle 
strength is dose-dependent (85). It is therefore important to titrate the dose in patients with 
an “incomplete” UMN lesion to reduce muscle tone sufficiently without inducing excessive 
weakness (and loss of function)(86). The appropriate time to initiate BoNT-A therapy in ULS 
should not be dependent on post- stroke duration, but rather on the goals initially set forth. 
In established spasticity, treatment should be based on the occurrence of impediments to 
occupational therapy or physiotherapy, or when the disability has reached a plateau or 
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when the disability continues to worsen despite such therapies (62). Predefined goals are 
ideally smart, achievable and person-centered, in order to optimize BoNT-A effects in areas 
of muscle tone, pain, active/passive functions, burden of care, cosmesis, among others(87). 
However, in early BoNT-A injection protocols, when spasticity is evolving, goals are likely 
different, as these are largely for prevention of contracture or possibly improvement in arm 
function in the long run. Finally, there are generally a couple of ways for which 
improvements in function can occur . Pre-morbid movement patterns may be regained first 
because of true motor recovery, and second, because of the redundancy in the number of 
degrees of freedom of the body(88). In the latter, actions can be accompanied by substitution 
of other degrees of freedom for movements of impaired joints. Such alternative movements 
or motor compensations(89) have also been observed in primates recovering from 
experimental stroke(90). Therefore, targeting specific muscle groups with BoNT-A, without 
affecting others, has the theoretical potential to unmask selective voluntary movement in 
situations where this is over-ridden by mass patterns of spasticity in antagonistic muscle 
groups(91). This underscores the interaction and complexity of proper (or improper) 
selection/targeting and accidental (or intentional) spread in achieving treatment goals. Last 
but not least, BoNT should not be administered alone, and its effects are best optimized in 
concert with a good rehabilitation program and an inter-disciplinary team. 
5. Conclusion  
Backed by robust clinical trials, we have undoubtedly reached a stage where the roles of 
BoNT in the management of dystonia and spasticity have been historically etched. This is 
paralleled by a BoNT safety profile that withstood the test of time over 20 years of 
application in hypertonic muscular disorders. The clinician is placed in a state to choose the 
best individualized approach to patients with dystonia and spasticity, bearing in mind that 
for BoNT, the evidences exist, as one negotiates through management issues related to 
benefit, harm and cost. 
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